secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0001854270-24-000022
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Biosciences Transfers to Nasdaq Capital Market, Gets Second Compliance Period
--------------------------------------------------------------------------------

- On Jan 23, 2024, Nasdaq approved transfer of Senti Biosciences common stock from Global Market to Capital Market, effective Jan 25.
- Nasdaq granted a second 180-day period until Aug 5, 2024, to meet $1.00 bid price requirement.
- Company must show closing bid price >= $1.00 for 10 consecutive business days to regain compliance.
- If not compliant by Aug 5, 2024, Nasdaq will delist SNTI; company may appeal to Hearings Panel.
- Senti Biosciences intends to consider a reverse stock split to cure the bid price deficiency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000022/0001854270-24-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000022/snti-20240206.htm
  HTML page:      https://secwatch.observer/filing/0001854270-24-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer